San Francisco
September 25, 2023

Welcome to hubXchange’s Antibody Therapeutics Xchange West Coast 2023, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics, through a series of roundtable discussions.

Discussion topics will cover Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multi-Specifics and Emerging Technologies.

Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: DoubleTree by Hilton San Francisco Airport, 835 Airport Blvd, Burlingame CA 94010-9949


  • Considerations and challenges guiding target selection in the development of antibody-based therapeutics for cancer
  • Challenges in the development of regenerative therapies in age-related chronic diseases
  • Strategies and considerations of discovering antibodies against novel targets
  • Antibody discovery strategies and optimization
  • HT screening and characterization assays
  • Using antibody-based modalities to remove pathogenic cell populations in non-oncology indications
  • Considerations for CAR-T/CAR-NK Cell binder format designs during screening and selections
  • Fc engineering for improved antibody drug ability
  • Application of computer aided design (CAAD) for therapeutic antibody development
  • Bi/tri-specific strategies for overcoming cell engager toxicity
  • CMC challenges of bi/multi specifics
  • CDR-H3 repertoire for antibody discovery
  • Next-generation platforms – Utilizing combinations of invitro, in vivo and in silico methods

Full Xchange Agenda

Click on each track for detailed agenda

Target Selection

Titles and Bullets
08:00 – 08:30
08:30 – 09:00

Opening Address & Keynote Presentation:

Overcoming challenges in engineering selectively functional agonist and antagonist bispecific therapeutic antibodies

Bispecific antibodies have the potential to unlock novel biology and elicit unique functionalities. ADS strategies for engineering bispecific antibodies with favorable functional and early developability profiles using target binders derived from immunizing AlivaMab® Mouse will be highlighted by case studies describing the engineering of dual-agonist and antagonist bispecific antibodies capable of selectively triggering function only when bound to two target antigens simultaneously

Vice President, Antibody Engineering and Protein Sciences, AlivaMab Discovery Services

Ankita has over 15 years of experience in drug discovery and preclinical development. Prior to AlivaMab Discovery Services, Ankita was VP, Antibody Engineering and Protein Sciences at Ichnos Therapeutics. Ankita has led projects across diverse therapeutic areas and enabled biologics design, production, characterization and preclinical development resulting in several candidate molecules in clinic.

Ankita Srivastava_HS
09:05 – 10:05

Considerations and challenges of target selection for antibody therapeutics in oncology

  • Specificity of target antigens
  • Matching target with appropriate drug modality tumour heterogeneity
  • Consideration of combination targets for multi-specifics

Director of Antibody Engineering, Cartography Biosciences

Alex Martinko is a protein engineer, chemical biologist, and biotech entrepreneur working to translate new technologies into next generation therapies. Currently he is co-founder and Sr. Director of Protein Engineering at Soteria Biotherapeutics where he is leading up the development of their T-LITE™ T-cell engager platform. Prior to Soteria, Alex completed his PhD in the lab of Jim Wells at UCSF, where he gained expertise in antibody engineering, chemical biology, proteomics, and cancer cell signalling.

Alex Martinko
10:10 – 10:40
1-2-1 Meetings/Networking Break
10:40 – 11:10
1-2-1 Meetings / Networking Break
11:10 – 11:20
Morning Refreshments
11:20 – 12:20

Lead Identification & Optimization: Generating drug-like antibodies from in vitro platforms

  • What constitutes a drug-like antibody?
    Can one generate drug-like antibodies from an in vitro platform?
  • What are the preferred antibody discovery platforms – in vitro vs in vivo antibody discovery? And why?
  • What sorts of affinities and diversities can be expected from in vitro platforms?
  • Can in vitro platforms be used to improve antibody affinities and developability?

VP Antibody Discovery, Specifica

Fortunato Ferrara has almost two decades in experience in recombinant antibody engineering and molecular immunology, mostly focused on antibody discovery using phage and yeast display platform.

Currently he serves as Vice President of Discovery Service as Specifica where he leads a team focused on selecting recombinant antibodies from the semi-synthetic Specifica proprietary libraries. His group continues to improve selection strategies against challenging targets or to obtain antibodies with very specific features.

Before joining Specifica, he was an Assistant Research Professor in Experimental Therapeutica at the Comprehensive Cancer Center of the University of New Mexico in Albuquerque. Previously, he was a postdoctoral fellow in the laboratory of Andrew Bradbury, at the Los Alamos National Laboratory. He has over 40 publications ( and he is co-inventor on several patents and patent applications.

He holds a PhD in Molecular Medicine and B.S. in Molecular Biology from the University of Trieste in Italy.

Fortunato Ferrara
12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

New Advancements in Antibody Production for Research

As the field of antibody drug development advances with novel technologies such as AI-designed molecules and bispecific antibodies (bsAbs), new challenges in research-phase production have arisen. This presentation showcases WuXi Biologics’ five innovative antibody production platforms: Ultra 96, 7-7-7, Quick’n Clean, Premium BsAb, and GramExpress. Each platform is designed to meet specific challenges presented by the latest trends in antibody drug research. Our solutions encompass ultra-high throughput, small-scale antibody production ideal for rapidly producing a large number of targets like AI-designed molecules, cost-effective identification of optimal bsAb pairings, and streamlined scale-up production for various types of antibodies.

Head of Protein Sciences, Vice President, WuXi Biologics

Jiansheng Wu is the Head of Protein Sciences and Vice President at WuXi Biologics.  With vast experience and expertise in protein sciences, he has been instrumental in establishing global protein production facilities and developing world-leading protein production technologies and platforms. Having participated in over 50 drug development projects, Jiansheng is a leading authority in automated expression, purification, and characterization of diverse proteins, from antibodies and antigens to enzymes and complex proteins. Previously at Genentech for 15 years, he made significant contributions to innovative protein expression and purification technologies.

Jiansheng Wu
13:50 – 14:20
1-2-1 Meetings / Networking Break
14:20 – 14:50
1-2-1 Meetings / Networking Break
14:50 – 15:20

Poster Session:

Lead Identification & Optimization topic: The future of developability profiling: AI-driven in silico immunogenicity screening and high throughput in vitro characterization

Antibody developability is a critical aspect of the drug discovery process that refers to the ability of an antibody to be developed into a safe, effective, and marketable therapeutic. IPA’s high throughput in silico and in vitro workflows allow for early comprehensive triage and lead candidate optimization. LENSᵃⁱ™ Integrated Intelligence Technology from BioStrand®, an IPA
subsidiary, powers the in silico immunogenicity screening workflow. By leveraging data from
over 1,800 clinical benchmarks, this workflow provides 3D structural models depicting each
candidate’s immunogenicity composite ranking from HLA binding predictions based on customizable phenotype distribution and humanness scoring referencing the complete human proteome. By combining over 12 in vitro assays with the in silico immunogenicity screening outputs, IPA provides a comprehensive data package that saves time and money while also
reducing risks in both clinical and post-commercialization phases.

VP Client Relations & Business Development, ImmunoPrecise Antibodies

Barry Duplantis serves as Vice President of Client Relations and Business Development (BD)
for IPA and is responsible for managing and coordinating all sales and BD related activities. He is a scientific entrepreneur and business development specialist with over 10 years of experience
in the commercial application of drug and vaccine discovery platforms. Prior to his appointment to VP of Client Relations & BD, he served as the Director of Client Relations for IPA (Canada) and
was the founder and CEO of DuVax Vaccine and Reagents. Dr. Duplantis obtained his Ph.D. from the Department of Microbiology and Biochemistry at the University of Victoria in 2012 with a focus on intracellular pathogenesis and vaccine development.

Barry Duplantis web
15:20 – 15:30
Afternoon Refreshments
15:30 – 16:00
1-2-1 Meetings / Networking Break
16:10 – 17:10

Developing second-generation therapeutic after a clinical failure

  • How to have stakeholders support after a failure?
  • Do we really know why it failed?
  • Can we use mouse models for human toxicity?

Vice President, Hengenix

Marco Muda
17:10 – 18:10
Evening Drinks Reception
Antibody Therapeutics Xchange | West Coast 2023